Review article: Chronic hepatitis B - Anti-viral or immunomodulatory therapy?

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 501-513

  Rijckborst, V ^a   Sonneveld, M J ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BLEEDING; BONE MARROW SUPPRESSION; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MYALGIA; NEPHROTOXICITY; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

EID: 79251496109     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04555.x     Document Type: Review

References (100)

1. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
3. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
4. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
5. Wong SN, Lok AS,. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12.
6. Hadziyannis SJ, Vassilopoulos D,. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
7. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10.
8. Locarnini S,. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (Suppl. 1): 3-10.
9. Feld JJ, Wong DK, Heathcote EJ,. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 5 (Suppl.): S96-102.
10. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 5 (Suppl.): S174-84.
11. Peters M,. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996; 23: 909-16.
12. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
13. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F,. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
14. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
15. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
17. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
18. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
19. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
20. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
21. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
22. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
23. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
24. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
25. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
26. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
27. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
28. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
29. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.
30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
31. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
32. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
33. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
34. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
35. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
36. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
37. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
38. Lampertico P, Vigano M, Facchetti F, et al. Effectiveness of entecavir for NUC-naîve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients. J Hepatol 2010; 52 (Suppl. 1): S389-90.
39. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
40. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
41. Heathcote EJ, Gane EJ, De Man RA, et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2009; 4 (Suppl.): 533A-4A.
42. Marcellin P, Buti M, Krastev Z, et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102); preliminary analysis. Hepatology 2009; 4 (Suppl.): 532A-3A.
43. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
44. Craxi A, Cooksley WG,. Pegylated interferons for chronic hepatitis B. Antiviral Res 2003; 60: 87-9.
45. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.
46. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
47. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
48. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
49. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
50. Lampertico P, Vigano M, Di Costanzo G, et al. Extended (2 years) treatment with peginterferon alfa-2a [40 kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010; 52 (Suppl. 1): S45.
51. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
52. Fontana RJ,. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 5 (Suppl.): S185-95.
53. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
54. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-8.
55. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 1163-71.
56. Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388-94.
57. Marcellin P, Avila C, Wursthorn K, et al. Telbivudine (LdT) plus peg-interferon (PEG-IFN) in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy. J Hepatol 2010; 52 (Suppl. 1): S6-7.
58. Sonneveld MJ, Janssen HL,. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010; 9: 91-8.
59. Terrault NA, Jacobson IM,. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 2007; 27 (Suppl. 1): 18-24.
60. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-13.
61. Wai CT, Chu CJ, Hussain M, Lok AS,. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
62. Fung SK, Lok AS,. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40: 790-2.
63. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-7.
64. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J,. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-56.
65. Chu CJ, Hussain M, Lok AS,. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-62.
66. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
67. Nguyen T, Desmond P, Locarnini S,. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009; 3: S5-15.
68. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
69. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
70. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8.
71. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
72. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
73. Lau GKK, Marcellin P, Brunetto M, et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50 (Suppl. 1): S333.
74. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL,. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
75. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
76. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
77. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
78. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
79. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
80. Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW,. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009; 50: 743-51.
81. Buti M, Brosa M, Casado MA, Rueda M, Esteban R,. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51: 640-6.
82. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010; 15: 145-55.
83. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
84. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL,. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
85. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-7.
86. Janssen HL, Reijnders JG,. Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us? J Hepatol 2009; 51: 1-3.
87. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
88. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS,. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
89. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL,. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
90. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44: 721-7.
91. Farci P, Marcellin P, Lu ZM, Diago M, Lai MY, Gurel S,. On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alpha-2a (40kDa) (Pegasys(R)). J Hepatol 2005; 42 (Suppl. 2): S175.
92. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
93. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14: 1165-74.
94. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alfa-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762-9.
95. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96-104.
96. Chan HL, Wong VW, Chim AM, et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12: 815-23.
97. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 728-35.
98. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48: 714-20.
99. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
100. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207-17.